Niki BioSolutions, Inc.NIKI
Price (close)
$4.97
Market cap
—
P/E
—
Revenue (FY)
—
Net income
-$1.4M
Dividend yield
—
1-year total return
-72.2%
Net margin
—
Revenue growth
—
Debt / equity
—
What Niki BioSolutions, Inc. does.
is a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to
treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases.
goal is to develop a broad range of novel and repurposed therapeutics and diagnostics technology across a wide range of disease/therapeutic
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | $1.5M | $1.3M | $431,378 | — | — |
| Net income | $4.9M | -$25.0M | -$9.8M | -$2.8M | -$4.3M | -$1.4M |
| Free cash flow | -$16.1M | -$14.8M | -$12.5M | -$7.7M | — | — |
More on NIKI.
- Niki BioSolutions, Inc. summary
- Niki BioSolutions, Inc. financial statements
- Niki BioSolutions, Inc. key metrics
- Niki BioSolutions, Inc. health scores and style box
- Niki BioSolutions, Inc. earnings
- Niki BioSolutions, Inc. dividends
- Niki BioSolutions, Inc. valuation
- Niki BioSolutions, Inc. ownership and insiders
- Niki BioSolutions, Inc. peers
Figures from Niki BioSolutions, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.